Imaging biomarker roadmap for cancer studies.
View/ Open
Date
2017-03-01ICR Author
Author
O'Connor, JPB
Aboagye, EO
Adams, JE
Aerts, HJWL
Barrington, SF
Beer, AJ
Boellaard, R
Bohndiek, SE
Brady, M
Brown, G
Buckley, DL
Chenevert, TL
Clarke, LP
Collette, S
Cook, GJ
deSouza, NM
Dickson, JC
Dive, C
Evelhoch, JL
Faivre-Finn, C
Gallagher, FA
Gilbert, FJ
Gillies, RJ
Goh, V
Griffiths, JR
Groves, AM
Halligan, S
Harris, AL
Hawkes, DJ
Hoekstra, OS
Huang, EP
Hutton, BF
Jackson, EF
Jayson, GC
Jones, A
Koh, D-M
Lacombe, D
Lambin, P
Lassau, N
Leach, MO
Lee, T-Y
Leen, EL
Lewis, JS
Liu, Y
Lythgoe, MF
Manoharan, P
Maxwell, RJ
Miles, KA
Morgan, B
Morris, S
Ng, T
Padhani, AR
Parker, GJM
Partridge, M
Pathak, AP
Peet, AC
Punwani, S
Reynolds, AR
Robinson, SP
Shankar, LK
Sharma, RA
Soloviev, D
Stroobants, S
Sullivan, DC
Taylor, SA
Tofts, PS
Tozer, GM
van Herk, M
Walker-Samuel, S
Wason, J
Williams, KJ
Workman, P
Yankeelov, TE
Brindle, KM
McShane, LM
Jackson, A
Waterton, JC
Type
Journal Article
Metadata
Show full item recordAbstract
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Research UK (CRUK) and the European Organisation for Research and Treatment of Cancer (EORTC) assembled experts to review, debate and summarize the challenges of IB validation and qualification. This consensus group has produced 14 key recommendations for accelerating the clinical translation of IBs, which highlight the role of parallel (rather than sequential) tracks of technical (assay) validation, biological/clinical validation and assessment of cost-effectiveness; the need for IB standardization and accreditation systems; the need to continually revisit IB precision; an alternative framework for biological/clinical validation of IBs; and the essential requirements for multicentre studies to qualify IBs for clinical use.
Collections
Subject
Humans
Neoplasms
Organotechnetium Compounds
Folic Acid
Fluorodeoxyglucose F18
Radiopharmaceuticals
Positron-Emission Tomography
Prognosis
Reproducibility of Results
Selection Bias
Research Design
Cost-Benefit Analysis
Biomarkers, Tumor
Clinical Decision-Making
Research team
Tumour Biology
Magnetic Resonance
Pre-Clinical MRI
Quantitative Biomedical Imaging
Language
eng
Date accepted
2016-10-11
License start date
2017-03
Citation
Nature reviews. Clinical oncology, 2017, 14 (3), pp. 169 - 186
Publisher
NATURE PORTFOLIO